Latest market price
29.62
-0.34-1.13%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -12.45 | Insider Own | 10.18% | Shs Outstand | 93.10M | Perf Week | -5.49% |
| Market Cap | 2.76B | Forward P/E | 16.04 | EPS next Y | 1.85 | Insider Trans | 0.00% | Shs Float | 87.06M | Perf Month | 5.56% |
| Enterprise Value | 5.15B | PEG | — | EPS next Q | 0.46 | Short Float | 24.05% | Perf Quarter | -6.47% | ||
| Income | -1.13B | P/S | 0.82 | EPS this Y | -21.72% | Short Ratio | 11.28 | Perf Half Y | 6.97% | ||
| Sales | 3.37B | P/B | 1.26 | EPS next Y | 20.99% | ROA | -20.31% | Short Interest | 20.94M | Perf YTD | 108.74% |
| Book/sh | 23.54 | P/C | 16.13 | EPS next 5Y | 23.43% | ROE | -50.02% | 52W High | 35.83 -17.33% | Perf Year | 35.87% |
| Cash/sh | 1.84 | P/FCF | — | EPS past 3/5Y | — | ROIC | 6.69% | 52W Low | 11.43 159.14% | Perf 3Y | -58.67% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 8.27% 9.65% | Gross Margin | 35.56% | Volatility | 4.53% 4.03% | Perf 5Y | -47.32% |
| Dividend TTM | — | EV/Sales | 1.53 | EPS Y/Y TTM | -924.82% | Oper. Margin | 10.06% | ATR (14) | 1.26 | Perf 10Y | -24.55% |
| Dividend Ex-Date | — | Quick Ratio | 1.56 | Sales Y/Y TTM | 4.27% | Profit Margin | -33.44% | RSI (14) | 48.26 | Recom | 2.36 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.57 | EPS Q/Q | -54.22% | SMA20 | -2.12% | Beta | 0.61 | Target Price | 35.38 |
| Payout | 0.00% | Debt/Eq | 1.17 | Sales Q/Q | -0.35% | SMA50 | 1.72% | Rel Volume | 0.80 | Prev Close | 29.96 |
| Employees | 25,000 | LT Debt/Eq | 1.15 | Earnings | Nov 04 | SMA200 | 14.45% | Avg Volume | 1.57M | Price | 29.62 |
| IPO Date | Mar 04, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.74% 2.56% | Net Debt/EBITDA | — | Volume | 1,256,297 | Change | -1.13% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-28-26 | Reiterated | Raymond James | Outperform | $25 → $39 |
| Sep-23-26 | Reiterated | Leerink Partners | Market Perform | $22 → $33 |
| Jul-30-26 | Reiterated | Guggenheim | Buy | $38 → $39 |
| Jul-30-26 | Reiterated | Barclays | Equal Weight | $25 → $32 |
| Jul-20-26 | Reiterated | Guggenheim | Buy | $31 → $38 |
| Jul-14-26 | Reiterated | Keybanc | Overweight | $30 → $40 |
| Jul-09-26 | Reiterated | UBS | Buy | $31 → $39 |
| Jun-03-26 | Upgrade | Jefferies | Hold → Buy | $25 → $30 |
| May-27-26 | Reiterated | KeyBanc | Overweight | $25 → $30 |
| May-04-26 | Reiterated | RBC Capital | Outperform | $17 → $31 |
Latest News· Times ET
Nov-02-26
Oct-29-26
Oct-27-26
Oct-21-26
Oct-15-26
Oct-13-26
Oct-13-2602:56PM
09:00AM
Oct-08-26
Oct-08-2601:11PM
Oct-07-26
Oct-06-26
Oct-06-2603:21AM
Oct-05-26
Sep-28-26
08:12AM
Sep-25-26
Sep-25-2604:05PM
Company
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient psychiatric hospitals, specialized treatment facilities, long-term residential centers, and outpatient clinics. As of March 31, 2022, the company managed an extensive network consisting of 238 behavioral healthcare facilities, collectively providing approximately 10,600 beds. Established in 2005, Acadia Healthcare is headquartered in Franklin, Tennessee.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,368 | 3,313 | 3,154 | 2,929 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,169 | 2,729 | 2,442 | 2,246 | — | — | — | — | — | |
| Gross Profit | 1,198 | 583 | 712 | 683 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 682 | 195 | 190 | 176 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 177 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 340 | 388 | 522 | 507 | — | — | — | — | — | |
| Interest Expense | 151 | 139 | 116 | 82 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,285 | -1,315 | -64 | -450 | — | — | — | — | — | |
| Net Income Before Taxes | -1,096 | -1,066 | 342 | -25 | — | — | — | — | — | |
| Income Taxes | 27 | 26 | 77 | -10 | — | — | — | — | — | |
| Consolidated Net Income | -1,127 | -1,103 | 256 | -22 | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,123 | -1,092 | 264 | -16 | — | — | — | — | — | |
| Net Income | -1,127 | -1,103 | 256 | -22 | — | — | — | — | — | |
| EPS (Recurring) | -12.45 | -12.16 | 2.79 | -0.24 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -12.45 | -12.16 | 2.79 | -0.24 | — | — | — | — | — | |
| EPS (Diluted) | -12.45 | -12.16 | 2.78 | -0.24 | — | — | — | — | — | |
| EBITDA | -684 | -738 | 608 | 189 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 14.26 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.80 | 0.39 | 1.16 | 2.42 | — | — | — | — | — | |
| Gross Margin | 35.57 | 17.60 | 22.57 | 23.32 | — | — | — | — | — | |
| Operating Margin | 10.10 | 11.71 | 16.55 | 17.31 | — | — | — | — | — | |
| Net Margin | -33.46 | -33.29 | 8.12 | -0.75 | — | — | — | — | — | |
| Shares Outstanding | 91 | 91 | 92 | 91 | — | — | — | — | — | |
| Market Capitalization | 2,695 | 1,291 | 3,648 | 7,076 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Miquelon Wade D | Director | Mar 05 '24 | Sale | 85.39 | 2,203 | 188,114 | 46,074 | Mar 06 |
| Gregg Vicky B | Director | Mar 04 '24 | Sale | 85.56 | 2,500 | 213,900 | 26,851 | Mar 06 |
| OSTEEN DEBRA K | Director | Dec 13 '23 | Sale | 77.67 | 35,000 | 2,718,450 | 675,833 | Dec 14 |
| OSTEEN DEBRA K | Director | Dec 12 '23 | Sale | 76.23 | 8,000 | 609,840 | 710,833 | Dec 14 |
| Hollinsworth John S. | EVP of Operations | Nov 14 '23 | Sale | 74.01 | 92,500 | 6,846,300 | 84,630 | Nov 16 |
| Hollinsworth John S. | EVP of Operations | Nov 10 '23 | Sale | 73.00 | 20,000 | 1,460,000 | 177,130 | Nov 13 |
| OSTEEN DEBRA K | Director | Nov 08 '23 | Sale | 74.21 | 15,000 | 1,113,150 | 718,833 | Nov 13 |
| Hollinsworth John S. | EVP of Operations | Nov 08 '23 | Sale | 74.50 | 12,500 | 931,250 | 197,130 | Nov 13 |
| GRIECO WILLIAM | Director | Sep 07 '22 | Sale | 82.54 | 5,000 | 412,700 | 73,811 | Sep 09 |
| Hollinsworth John S. | EVP of Operations | Aug 04 '22 | Sale | 80.68 | 10,780 | 869,730 | 80,559 | Aug 08 |
| Duckworth David M. | Chief Financial Officer | Aug 04 '22 | Sale | 80.63 | 26,921 | 2,170,677 | 99,263 | Aug 08 |
| Howard Christopher L | EVP, GC and Secretary | Aug 04 '22 | Option Exercise | 50.75 | 12,274 | 622,906 | 169,804 | Aug 08 |
| Howard Christopher L | EVP, GC and Secretary | Aug 04 '22 | Sale | 81.60 | 20,657 | 1,685,706 | 149,147 | Aug 08 |
| Petrie William M | Director | Jul 29 '22 | Sale | 83.42 | 6,000 | 500,520 | 31,769 | Aug 02 |
| WAUD REEVE B | Director | Jun 14 '21 | Sale | 66.47 | 55,030 | 3,657,844 | 506,844 | Jun 16 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.